BELLUS Health Inc. (TSE:BLU – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q2 2022 EPS estimates for BELLUS Health in a research note issued to investors on Tuesday, July 12th. Jefferies Financial Group analyst S. Jeong expects that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for BELLUS Health’s current full-year earnings is ($0.95) per share. Jefferies Financial Group also issued estimates for BELLUS Health’s Q3 2022 earnings at ($0.27) EPS, Q4 2022 earnings at ($0.38) EPS, FY2022 earnings at ($1.04) EPS, FY2023 earnings at ($1.43) EPS, FY2024 earnings at ($1.46) EPS, FY2025 earnings at ($1.18) EPS and FY2026 earnings at ($1.27) EPS.
Separately, HC Wainwright reiterated a “buy” rating and set a C$16.00 target price on shares of BELLUS Health in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of C$15.75.
BELLUS Health Price Performance
BLU stock opened at C$11.95 on Friday. The firm has a 50 day moving average price of C$10.97 and a 200-day moving average price of C$9.59. BELLUS Health has a 52-week low of C$3.32 and a 52-week high of C$14.46. The firm has a market capitalization of C$1.28 billion and a price-to-earnings ratio of -11.23. The company has a debt-to-equity ratio of 0.30, a quick ratio of 14.75 and a current ratio of 15.33.
BELLUS Health (TSE:BLU – Get Rating) last released its earnings results on Wednesday, May 11th. The company reported C($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.23) by C$0.07. The business had revenue of C$0.01 million for the quarter, compared to analysts’ expectations of C$0.01 million.
About BELLUS Health
BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Receive News & Ratings for BELLUS Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BELLUS Health and related companies with MarketBeat.com’s FREE daily email newsletter.